Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Binding of miR-3036-5p to CYP18A1 can be prevented by an A-to-I RNA editing, thus elevating CYP18A1 expression, decreasing 20E titer, and finally regulating the wing dimorphism of offspring in aphid.